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Abstract
Background Acute sore throat (pharyngitis) is one of the
most common illnesses for which children are seen by
primary care physicians. Most cases are caused by viruses
and are benign and self-limiting. Clinically proven, over-
the-counter throat lozenges provide rapid and effective
relief of acute sore throat symptoms, and are increasingly
important in self-management of this condition.
Objective The purpose of this study (International
Standard Randomized Controlled Trial Number:
ISRCTN34958871) was to evaluate the acceptability of
two licensed, commercially available sore throat lozenges
containing amylmetacresol and 2,4-dichlorobenzyl (AMC/
DCBA)—one strawberry flavored and the other orange
flavored—in healthy children.
Study design This was an open-label, single-dose, cross-
over, taste-testing study in children recruited via a clinical
database and advertisements over a 3.5-week period.
Setting Potentially eligible participants were invited to
attend the taste-testing session at a clinic.
Participants At the screening session, which took place
either before or on the day of taste testing, details of rel-
evant medical history, medication, and demographics were
recorded. Of the 108 screened subjects, 102 were recruited.
These were healthy male and female children aged
6–12 years.
Intervention Each child cleansed their palate with water
and water biscuits before tasting a strawberry-flavored
lozenge (Strepsils strawberry sugar free, Reckitt Benck-
iser Healthcare Limited, Nottingham, UK; PL
00063/0395), which was sucked for 1 minute and then
expelled. The orange-flavored lozenge (Strepsils orange
with vitamin C, Reckitt Benckiser Healthcare Limited,
Nottingham, UK; PL 016242152) was tasted at least 15
minutes later following further cleansing of the palate. The
spontaneous reaction of the child on tasting each lozenge
was observed and recorded. Subjects were asked to indicate
their liking for each lozenge, using a 7-point hedonic facial
scale, and were required to answer a series of questions
relating to what they liked and disliked about the taste and
the feel of the lozenge in the mouth and throat. The primary
endpoint was the proportion of subjects with a hedonic
facial score of [4. Secondary endpoints included the
spontaneous reaction of the child on tasting the lozenge and
responses to questions related to taste.
Results The taste of the lozenge was scored [4 (i.e.
‘good’, ‘really good’, or ‘super good’) by 85.3 % of sub-
jects for the strawberry flavor and 49.0 % for the orange
flavor (p \ 0.0001). The mean (standard deviation) score
was 5.72 (1) for the strawberry-flavored lozenge and 4.35
(2) for the orange-flavored lozenge. The proportion of
subjects willing to take the lozenge again was 94 % for the
strawberry flavor and 56 % for the orange flavor.
Conclusions Strawberry-flavored AMC/DCBA lozenges
were liked by, and acceptable to, the majority of the
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children. AMC/DCBA orange-flavored lozenges were also
liked by, and acceptable to, approximately half the chil-
dren. Overall, both strawberry and orange would be suit-
able flavors for lozenges intended for children when they
suffer from sore throat.
1 Introduction
Acute sore throat (pharyngitis) is one of the most common
illnesses for which children and their parents visit primary
care physicians [1]. For example, in the ambulatory setting,
acute pharyngitis accounts for around 1 % of primary care
visits [2]. Most cases (up to 80 %) are caused by viruses
and are benign and self-limiting [3]. However, bacteria
(e.g. group A beta-hemolytic streptococci) are another
common cause, particularly among children [4].
The diagnosis of pharyngitis must distinguish children
with viral pharyngitis, who would not benefit from antibi-
otic therapy, from those children with group A beta-
hemolytic streptococcal pharyngitis, for whom antibiotics
are appropriate [1]. Making this distinction is crucial in
attempting to minimize the unnecessary use of antimicro-
bial agents in children and providing suitable symptomatic
relief. The absence of fever or the presence of clinical
features such as conjunctivitis, cough, or hoarseness, sug-
gest a viral etiology [1].
The clinical manifestations of acute sore throat are related
to inflammation of the pharynx and/or tonsils, and include
pain, redness, heat, and swelling [5, 6]. Despite the fact that
antibiotics are still often requested and prescribed for acute
sore throat, many patients (adults and children) consult their
primary care physician to establish the cause of the symp-
toms, to obtain pain relief, and for information on the course
of the disease [7, 8]. Furthermore, because the majority of
sore throats are caused by viruses and not bacteria, antibi-
otics are generally ineffective and not recommended by
clinical bodies for primary treatment of sore throat [9].
Instead, clinically proven over-the-counter (OTC) medica-
tions, which provide rapid and effective relief of symptoms
of acute sore throat, regardless of cause, are increasingly
important in the self-management of this condition.
Throat lozenges containing amylmetacresol (AMC) and
2,4-dichlorobenzyl alcohol (DCBA), which possess anti-
bacterial, antiviral, and local anesthetic properties, provide
symptomatic relief of sore throat [6, 10]. They are licensed
for OTC use in the UK and around the world for adults and
children for the symptomatic relief of mouth and throat
infections [11]. Safety profiles are well established, and in
some countries the lozenges have been used for over
50 years.
Lozenges containing AMC/DCBA have been studied in
several clinical trials conducted in adults and have
demonstrated significant analgesic, functional, sensorial,
and psychological effects from as early as 1–5 minutes and
lasting up to 2 h post-dose [5, 12, 13]. For example, studies
have shown that patients taking AMC/DCBA throat loz-
enges reported experiencing relief from their throat sore-
ness and sore throat pain but also soothing and coating
effects [5, 14]. These lozenges have also been shown to be
effective for the symptomatic treatment of sore throat in
children aged [5 years with acute and aggravated chronic
pharyngitis [15].
A primary consideration for the development of a
pediatric formulation is the acceptability to children [16].
Many investigators cite palatability as an important factor
in medication adherence and completion of therapy in
children, although formal studies are lacking [17]. Little
direct evidence exists to show that poor palatability
decreases adherence; however, it is not unreasonable to
assume that a more palatable medication is easier to
administer to infants and young children. Previous taste
testing in children has shown that they generally prefer
sweet preparations with fruit flavors [18]. National favor-
ites are bubble gum and grape in the USA, citrus and red
berries in Europe, and liquorice in Scandinavia [16].
The hedonic facial scale, which uses a pictorial scale of
facial expressions, has been commonly employed in
determining the acceptability of medications to children
[18]. Compared with spontaneous verbal judgment, this
method has the advantage of being more standardized.
Studies have shown that children aged as young as 4 years
can understand and use this scale to indicate whether a
substance tastes pleasant and is therefore acceptable [18].
This scale has previously been used to evaluate the
acceptability of a wide range of medications among
children, including steroid preparations [19], antibiotics
[20–22], calcium and vitamin D3 [23, 24], ondansetron
[25], and lansoprazole [26, 27].
The purpose of this study was to evaluate the accept-
ability of two licensed, commercially available throat loz-
enges containing AMC/DCBA, one strawberry and the
other orange flavored, in healthy children aged 6–12 years,
taken sequentially on the taste-testing day. Taste was
assessed using the 7-point hedonic facial score, which was
the primary measure of acceptability, as well as spontane-
ous reaction and verbal responses to questions relating to
palatability, flavor, and the feel of the lozenge in the mouth.
2 Methods
2.1 Study Design
This was an open-label, single-dose, crossover, taste-test-
ing study in children to investigate the acceptability of two
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different flavors of AMC/DCBA lozenges. It was con-
ducted in accordance with the Declaration of Helsinki [28]
and was reviewed by the Reading Independent Ethics
Committee (Reading, Berkshire, UK). The International
Standard Randomized Controlled Trial Number is
ISRCTN34958871.
As this study was designed to assess the acceptability of
the two lozenge flavors in absolute rather than comparative
terms, blinding was not considered necessary given that
flavor acceptability, as opposed to efficacy, was the
parameter of interest and would have been difficult to
achieve as the products taste different.
The subject population comprised healthy children aged
6–12 years, the age range of the target population.
Although no formal sample size calculation was per-
formed, 100 children tasting both samples were believed to
be an appropriate sample number to evaluate. It was esti-
mated that 120 subjects would need to be screened in order
to achieve this.
2.2 Subject Selection
Healthy males and females (aged 6–12 years) were
recruited from a clinical trial company’s database and via
advertisements over a 3.5-week period. Parents provided
written informed consent for the participation of their child
in the study, and the child voluntarily wrote or marked their
name on the assent form. Subjects were screened either
before or on the day of taste testing, and details of any
relevant medical history, medication, and demographics
were recorded.
Subjects were excluded if they had a history of
hereditary fructose intolerance; sensitivity to an analgesic
medication, its ingredients or related products; or any
previous history of allergy or known intolerance to AMC,
DCBA, or any colouring, flavoring, preservative, sweet-
ener, or surfactant. Other exclusion criteria were a history
of hepatic or renal impairment, cardiac disease, high blood
pressure, asthma, gastrointestinal disorders, respiratory
infection, or any other condition that could have affected
the subjects’ perception of taste. Subjects were also
excluded from enrolment on the taste-testing day if they
had taken prescription medications during the previous
7 days, used analgesics or anesthetics, consumed food or
drink that may have affected their perception of taste (e.g.
highly spiced meals or mint- or menthol-based products)
on the testing day, or used non-prescription medication
within 4 h prior to taste testing. Other restrictions on the
taste-testing day were the presence of a mouth ulcer or
dental work carried out on that day. The taste-testing day
was to be rescheduled for subjects who met any one of
these restriction criteria.
2.3 Treatments
Before receiving a lozenge, each subject cleansed their pal-
ate with water and water biscuits. The subjects received a
single strawberry-flavored, sugar-free AMC/DCBA lozenge
(Strepsils strawberry sugar free, Reckitt Benckiser
Healthcare Limited, Nottingham, UK; PL 00063/0395) fol-
lowed at least 15 minutes later by a single orange-flavored,
colour-free AMC/DCBA lozenge (Strepsils orange with
vitamin C, Reckitt Benckiser Healthcare Limited, Notting-
ham, UK; PL 016242152). Each lozenge was sucked for
1 minute and then expelled. Both lozenges contained 0.6 mg
AMC and 1.2 mg DCBA. In addition, the orange-flavored
colour-free lozenge contained 100 mg vitamin C as sodium
ascorbate/ascorbic acid. Questions relating to the lozenges’
palatability were then asked after each lozenge was spat out.
During protocol development, there were concerns that if
the orange-flavored lozenge was tasted first, the strong
orange and menthol flavor might affect the subsequent
perception of the strawberry flavor, even after the required
15-minute interval and cleansing of the palate. Therefore,
the strawberry-flavored lozenge was tasted first by all sub-
jects. This was deemed acceptable given that the purpose of
the study was to assess the acceptability of each flavor and
not to compare the acceptability of the two flavors. The
15-minutes period between tasting the samples was con-
sidered appropriate in terms of maximizing subject com-
pliance. A previous study has shown that complete lozenge
dissolution takes approximately 6.77 minutes [29]. As the
children in this study were only required to suck each loz-
enge for 1 minutes, they were not exposed to more than a
standard dose (AMC 0.0022 mg/mL [standard deviation
(SD) 0.0012] and DCBA 0.0097 mg/mL [SD 0.0040]).
2.4 Acceptability Assessments and Endpoints
Assessments on the taste-testing day were designed to
evaluate the acceptability of both flavors to the children.
During the taste-testing session, children were first asked
what they would like their medication to taste of. Subjects
were asked to indicate their liking for each lozenge, using a
7-point hedonic facial scale (Fig. 1), which included the
following scores: 1 = super bad; 2 = really bad; 3 = bad;
4 = may be good/may be bad; 5 = good; 6 = really good;
7 = super good. After expelling the lozenge, the subjects
were asked a series of questions relating to the taste and
feel of the lozenge in the mouth and throat.
The primary endpoint was the percentage of children
who rated each lozenge with a score of [4 on the 7-point
hedonic facial scale, together with descriptive summary
statistics (mean, SD, median, minimum, maximum) of the
hedonic facial scale scores.
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Secondary endpoints included the observed spontaneous
reaction to putting the lozenge in the subject’s mouth
(based on whether the subjects sucked the lozenge for 1
minute or spat it out), the flavor perceived by the subjects
in response to the question ‘‘What does the medicine taste
of?’’, and the subjects’ responses to a series of questions
about what they liked and disliked about the taste.
No efficacy assessments were conducted in this study.
Assessment of safety included analysis of any adverse
events (AEs) spontaneously mentioned by the subjects after
they had received each flavor of lozenge.
2.5 Statistical Methods
For the primary endpoint, the proportion of subjects who
had a hedonic facial score of [4 (i.e., 5–7) was presented
together with the 95 % confidence interval (CI), for each
lozenge. For the secondary endpoints, descriptive summary
statistics of the hedonic facial scale score for each lozenge
were presented together with the 95 % CI for the mean
score. The number of times the sample was retained for 1
minute/spat out and responses to questions relating to taste
were presented in the listings and summarized
descriptively.
3 Results
A total of 108 subjects were screened, of whom 103 were
eligible and entered the study (59 males; 44 females), with
a mean age of 9 years (range 6–12 years). Medical history
was reported for 19 subjects. One subject withdrew before
tasting the first sample. A total of 102 subjects completed
the study, tasting both samples, and were included in the
analyses.
3.1 Acceptability Analyses
In response to the question ‘‘If you could choose the taste
of your medicine, what would it taste of?’’, 44 % of sub-
jects indicated their preference would be strawberry/
strawberries, 11 % chocolate, and 7 % orange. For the
primary endpoint, 85.3 % of subjects rated the strawberry
lozenge with a score of [4 and 49.0 % rated the orange-
flavored lozenge with a score of [4 (p \ 0.0001)
(Table 1). The mean (SD) score was 5.72 (1) for the
strawberry-flavored lozenge and 4.35 (2) for the orange-
flavored lozenge (Table 2).
No subject spontaneously rejected either lozenge or spat
it out before being required to do so. When asked directly,
the proportion of subjects who had wanted to take the loz-
enge out of their mouth was 17 % for the strawberry flavor
and 46 % for the orange flavor. The proportion of these
subjects who wanted to remove the lozenge and who also
rated the lozenges as ‘super bad’/‘really bad’, or ‘bad’ was
4 % for strawberry and 26.5 % for orange. The proportion
of subjects answering ‘‘yes’’ to the question ‘‘Would you be
happy to take it again?’’ was 94 % for the strawberry loz-
enge and 56 % for the orange lozenge. The most common
















Fig. 1 The 7-point hedonic facial scale for assessment of acceptability [16]
Table 1 Proportion of subjects selecting each score on a 7-point
hedonic facial scale (primary endpoint)
Percentage of subjects selecting each
scorea
Strawberry-flavored
lozenge (n = 102)
Orange-flavored
lozenge (n = 102)
Score
1: Super bad 2.0 9.8
2: Really bad 1.0 5.9
3: Bad 1.0 12.7
4: May be good/may
be bad
10.8 22.5
5: Good 17.6 22.5
6: Really good 40.2 12.7
7: Super good 27.5 13.7
Percentage [95 % CI] of
subjects selecting a
score [4
85.3 [74.8–92.2] 49.0 [39.3–58.7]
p value for difference
between treatments
\0.0001
a Numbers may not total 100 %, because of rounding
CI confidence interval
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that it tasted ‘‘sour’’ (13 % of subjects). The proportion of
subjects answering ‘‘yes’’ to the question ‘‘Would you be
happy for Mum or Dad to give you this flavor medicine
when you get a sore throat?’’ was 86 % for the strawberry-
flavored lozenge and 55 % for the orange-flavored lozenge.
When asked the specific question ‘‘Did your mouth feel
soothed?’’, a high proportion of subjects taking either the
strawberry (87 %) or orange (67 %) lozenge reported that
their throat had been soothed by the lozenge.
When the subjects were asked how the medicine had made
their throat feel, their responses were broadly similar for both
lozenges; the proportion of subjects whose throat felt ‘‘nor-
mal’’, whose throat felt ‘‘not different’’, or who did not know
was 41 and 32 % for the strawberry- and orange-flavored
lozenges, respectively (Table 3). These results were expec-
ted, as the study was conducted in healthy volunteers.
No AEs were reported in this study, which is in accor-
dance with the well-established safety profile of AMC/
DCBA lozenges.
4 Discussion
The palatability of medications, particularly those taken
orally, is an important factor in determining medication
adherence and completion of drug therapy in young chil-
dren, and should be an important part in the development
process of new pediatric formulations [16]. This taste-
testing study was based on well-recognised and accepted
techniques for evaluating the taste of pediatric formulations
[30, 31] and, based on the results of this study, would seem
to be applicable to lozenge formulations.
In this study, a high proportion (85.3 %) of the children
rated the strawberry-flavored lozenge as tasting ‘good’,
‘really good’, or ‘super good’. These results are consistent
with those of other studies of strawberry-flavored medica-
tions in children. For example, in an assessment of antibi-
otics, Angelilli et al. [22] found that a strawberry-flavored
cefixime preparation was most commonly rated as the best
tasting when compared with cherry-, bubble gum- and
banana-flavored preparations in children aged 5–8 years. In
a further study, strawberry-flavored lansoprazole suspen-
sion and tablets were preferred by over 90 % of children
(5–11 years), compared with peppermint-flavored raniti-
dine syrup [26, 27]. In another study, significantly more
Table 2 Descriptive summary statistics of the 7-point hedonic facial
scale for all subjects (primary endpoint)
Hedonic facial scale score
Strawberry-flavored
lozenge (n = 102)
Orange-flavored
lozenge (n = 102)
Mean scores in different age groups
6 years [n = 13] 6.15 4.62
7 years [n = 6] 5.33 4.33
8 years [n = 16]a 5.60 3.93
9 years [n = 20] 5.75 3.90
10 years [n = 15] 5.20 4.87
11 years [n = 14] 6.07 4.71










a One subject withdrew from the study before tasting either lozenge
SD standard deviation, SEM standard error of the mean, UCL upper
confidence limit, LCL lower confidence limit
Table 3 Subjects’ responses to the questions ‘‘How did it make your mouth feel?’’ and ‘‘How did it make your throat feel?’’












36 6 41 32
Generally positive 19 9 26 19
Smooth/soothed/soft/
calm
5 3 16 14
Tingly/numb 17 24 6 12
Generally negative 4 14 4 6
Hot 3 12 NR NR
NR not reported
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children (aged 3–12 years) preferred strawberry-flavored
ondansetron syrup to grape-flavored syrup [25].
However, one strawberry flavor or other flavor may taste
quite different to another, depending on the flavor supplier,
the medicinal format of the product containing the flavor,
or other ingredients with a taste within the formulation,
such as the active ingredients. We demonstrated that these
particular flavors in AMC/DCBA lozenges were liked by a
majority of children within this study.
A previous study conducted in children aged 4–7 years
found that sweetness was the most important flavor char-
acteristic for a medication, together with the effective
masking of any bitter taste of the active ingredients [32]. In
addition, red fruit (strawberry/raspberry) flavor was found
to be the most acceptable to children and although the
majority readily accepted citrus flavors, they did not prefer
them. Citrus flavor was preferred to banana flavor by fewer
children when compared with formulations containing
calcium and vitamin D3 [24]. Therefore, in our study, the
sourness of the flavor may have been a factor, with the
lower absolute palatability of the orange-flavored lozenge
being in line with the major dislike reported in this study.
The open-label, uncontrolled design of the study was
appropriate given that the objective was to investigate
absolute rather than comparative acceptability of the
samples. The order in which the samples were tasted was
not randomized because of the possibility that the menthol
in the orange-flavored lozenge could carry over and affect
the taste of the strawberry-flavored lozenge, as menthol in
lozenges has been demonstrated to exert effects that are
still experienced 30 minutes after consumption [33].
Therefore, the strawberry-flavored lozenge was taken
before the orange-flavored lozenge.
A potential limitation of this study is that it was con-
ducted in healthy children, and thus the results may not
necessarily be translated directly to children with acute
sore throat, whose perceptions of flavor may be affected by
symptoms of a cold [34]. However, since the main purpose
of this study was to evaluate the general acceptability of
the two flavored lozenges in absolute rather than compar-
ative terms, and the impact of symptoms of a cold on
perception of flavor may differ between subjects, the
inclusion of healthy children in this study is considered
reasonable. Future work may be warranted involving
children with symptoms of upper respiratory tract infec-
tion/sore throat.
It is also possible that the order in which the lozenges
were tasted (strawberry then orange) had a bearing on the
vocabulary used in the responses given to the question
asking what the subjects disliked about the flavor. After
being asked general questions about what they liked/dis-
liked about the strawberry lozenge, subjects were then
asked more specific questions such as ‘‘Do you think it
tasted sour [like a lemon]?’’. The subjects then tasted the
orange-flavored lozenge and were asked the same questions
in the same order. Therefore, when subjects were volun-
tarily describing the taste of the strawberry-flavored loz-
enge, they had not yet been presented with the words
‘‘sour’’ or ‘‘lemon’’, but when they were describing the
orange-flavored lozenge, they had already been given the
association of ‘‘sour’’ and ‘‘lemon’’.
5 Conclusions
Strawberry-flavored sugar-free AMC/DCBA lozenges were
liked by, and acceptable to, the majority of the children in
this study; this flavor preference is in line with previous
children’s medicine studies in Europe. Orange-flavored
colour-free AMC/DCBA lozenges with vitamin C were
liked by, and acceptable to, approximately half of the chil-
dren, and older children (10–12 years) found them more
acceptable than 6- to 10-year-olds did. Overall, both
strawberry and orange would be suitable flavors for lozenges
intended for children when they suffer from sore throat.
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